Literature DB >> 19913550

Progressive loss of creatine maintains a near normal DeltaG approximately (ATP) in transgenic mouse hearts with cardiomyopathy caused by overexpressing Gsalpha.

Weiqun Shen1, Dorothy E Vatner, Stephen F Vatner, Joanne S Ingwall.   

Abstract

Myocardial [ATP] falls in the failing heart. One potential compensatory mechanism for maintaining a near normal free energy of ATP hydrolysis (DeltaG approximately (ATP)), despite a fall in [ATP], may be the reduction of myocardial creatine (Cr). To test this, we conducted a longitudinal study using transgenic mice overexpressing cardiac Gsalpha, which slowly developed cardiomyopathy. Myocardial energetics measured using (31)P NMR spectroscopy and isovolumic contractile performance were determined in perfused hearts isolated from 5-, 10-, 17-month-old Gsalpha and age-matched littermate wild type (WT) mice. In young Gsalpha hearts, contractile performance was enhanced with near normal cardiac energetics. With age, as contractile performance progressively decreased in Gsalpha hearts, [ATP] and [PCr] progressively decreased while [Pi] increased only modestly; no changes were observed in WT hearts. Myocardial (but not skeletal) [Cr] in Gsalpha mice decreased, beginning at an early age (1.5 months). Consequently, cytosolic [ADP] and the free energy available from ATP hydrolysis were maintained at normal levels in Gsalpha hearts, despite decreased [ATP]. During increased cardiac work caused by supplying isoproterenol, the relationship between the rate pressure product (RPP) and DeltaG approximately (ATP) in Gsalpha mouse hearts demonstrated an increased cost of contraction in failing hearts. Thus, our results suggest that the decrease of myocardial [Cr] and net Pi efflux play compensatory roles by maintaining a nearly normal free energy of ATP hydrolysis in the dysfunctional heart; however, it also increased the cost of contraction, which may contribute to the lower contractile reserve in the failing heart. Copyright (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19913550      PMCID: PMC2837793          DOI: 10.1016/j.yjmcc.2009.10.029

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  34 in total

1.  Overexpression of Gs alpha protein in the hearts of transgenic mice.

Authors:  C Gaudin; Y Ishikawa; D C Wight; V Mahdavi; B Nadal-Ginard; T E Wagner; D E Vatner; C J Homcy
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

2.  Response of myocardial metabolites to graded regional ischemia: 31P NMR spectroscopy of porcine myocardium in vivo.

Authors:  S Schaefer; S A Camacho; J Gober; R G Obregon; M A DeGroot; E H Botvinick; B Massie; M W Weiner
Journal:  Circ Res       Date:  1989-05       Impact factor: 17.367

3.  Stabilization of a derangement in adenosine triphosphate metabolism during sustained, partial ischemia in the dog heart.

Authors:  W A Neill; J S Ingwall
Journal:  J Am Coll Cardiol       Date:  1986-10       Impact factor: 24.094

Review 4.  Time course and mechanisms of contractile dysfunction during acute myocardial ischemia.

Authors:  B D Guth; R Schulz; G Heusch
Journal:  Circulation       Date:  1993-05       Impact factor: 29.690

5.  High-energy phosphate responses to tachycardia and inotropic stimulation in left ventricular hypertrophy.

Authors:  R J Bache; J Zhang; G Path; H Merkle; K Hendrich; A H From; K Ugurbil
Journal:  Am J Physiol       Date:  1994-05

6.  31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure.

Authors:  S Neubauer; T Krahe; R Schindler; M Horn; H Hillenbrand; C Entzeroth; H Mader; E P Kromer; G A Riegger; K Lackner
Journal:  Circulation       Date:  1992-12       Impact factor: 29.690

7.  Effects of norepinephrine infusion on myocardial high-energy phosphate content and turnover in the living rat.

Authors:  J A Bittl; J A Balschi; J S Ingwall
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

8.  Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy.

Authors:  C J Hardy; R G Weiss; P A Bottomley; G Gerstenblith
Journal:  Am Heart J       Date:  1991-09       Impact factor: 4.749

9.  Acidosis during ischemia promotes adenosine triphosphate resynthesis in postischemic rat heart. In vivo regulation of 5'-nucleotidase.

Authors:  M I Bak; J S Ingwall
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

10.  Adverse effects of chronic endogenous sympathetic drive induced by cardiac GS alpha overexpression.

Authors:  M Iwase; S P Bishop; M Uechi; D E Vatner; R P Shannon; R K Kudej; D C Wight; T E Wagner; Y Ishikawa; C J Homcy; S F Vatner
Journal:  Circ Res       Date:  1996-04       Impact factor: 17.367

View more
  9 in total

Review 1.  Targeting myocardial substrate metabolism in heart failure: potential for new therapies.

Authors:  Hossein Ardehali; Hani N Sabbah; Michael A Burke; Satyam Sarma; Peter P Liu; John G F Cleland; Aldo Maggioni; Gregg C Fonarow; E Dale Abel; Umberto Campia; Mihai Gheorghiade
Journal:  Eur J Heart Fail       Date:  2012-02       Impact factor: 15.534

Review 2.  Mechanisms of altered Ca²⁺ handling in heart failure.

Authors:  Min Luo; Mark E Anderson
Journal:  Circ Res       Date:  2013-08-30       Impact factor: 17.367

3.  Metabolic Therapy in Heart Failure.

Authors:  Yury Lopatin
Journal:  Card Fail Rev       Date:  2015-10

4.  Decreased ATP production and myocardial contractile reserve in metabolic heart disease.

Authors:  Ivan Luptak; Aaron L Sverdlov; Marcello Panagia; Fuzhong Qin; David R Pimentel; Dominique Croteau; Deborah A Siwik; Joanne S Ingwall; Markus M Bachschmid; James A Balschi; Wilson S Colucci
Journal:  J Mol Cell Cardiol       Date:  2018-02-01       Impact factor: 5.000

5.  Smooth muscle-specific Gsα deletion exaggerates angiotensin II-induced abdominal aortic aneurysm formation in mice in vivo.

Authors:  Xiaoteng Qin; Lifan He; Mi Tian; Ping Hu; Jianmin Yang; Huixia Lu; Wenqiang Chen; Xiuxin Jiang; Cheng Zhang; Jiangang Gao; Min Chen; Lee S Weinstein; Yun Zhang; Wencheng Zhang
Journal:  J Mol Cell Cardiol       Date:  2019-05-07       Impact factor: 5.000

Review 6.  AMPK: a therapeutic target of heart failure-not only metabolism regulation.

Authors:  Xuan Li; Jia Liu; Qingguo Lu; Di Ren; Xiaodong Sun; Thomas Rousselle; Yi Tan; Ji Li
Journal:  Biosci Rep       Date:  2019-01-03       Impact factor: 3.840

Review 7.  Creatine deficiency and heart failure.

Authors:  Annamaria Del Franco; Giuseppe Ambrosio; Laura Baroncelli; Tommaso Pizzorusso; Andrea Barison; Iacopo Olivotto; Fabio A Recchia; Carlo M Lombardi; Marco Metra; Yu F Ferrari Chen; Claudio Passino; Michele Emdin; Giuseppe Vergaro
Journal:  Heart Fail Rev       Date:  2021-10-07       Impact factor: 4.654

Review 8.  (1)H-MR spectroscopy for analysis of cardiac lipid and creatine metabolism.

Authors:  Kiterie M E Faller; Craig A Lygate; Stefan Neubauer; Jürgen E Schneider
Journal:  Heart Fail Rev       Date:  2013-09       Impact factor: 4.214

Review 9.  Use of cardiac magnetic resonance to detect changes in metabolism in heart failure.

Authors:  William D Watson; Jack J J Miller; Andrew Lewis; Stefan Neubauer; Damian Tyler; Oliver J Rider; Ladislav Valkovič
Journal:  Cardiovasc Diagn Ther       Date:  2020-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.